Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: A success story to usher in the second decade of molecular targeted therapy in oncology

Oncologist

Volumn 17, Issue 11, 2012, Pages 1351-1375

  Ou, Sai Hong Ignatius ^a   Bartlett, Cynthia Huang ^b   Mino Kenudson, Mari ^c   Cui, Jean ^d   Iafrate, A John ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Pfizer Ltd   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

ALK inhibitor; Chromosomal rearrangements; Crizotinib; MET inhibitor; Non small cell lung cancer (NSCLC); Receptor tyrosine kinase fusion positive malignancies; ROS1 inhibitor

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; CYTOCHROME P450 3A; DACOMITINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GANETESPIB; GEFITINIB; IMATINIB; MIDAZOLAM; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 3; PEMETREXED; PLATINUM; PROTEIN TYROSINE KINASE INHIBITOR; RETASPIMYCIN; SCATTER FACTOR RECEPTOR;

ARTICLE; BRAIN METASTASIS; CANCER GROWTH; CANCER SURVIVAL; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG METABOLISM; DRUG SCREENING; DRUG WITHDRAWAL; ENZYME ACTIVATION; ETHNICITY; FATIGUE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL STROMAL TUMOR; GENE; GENE REARRANGEMENT; HUMAN; IMMUNOHISTOCHEMISTRY; INTERSTITIAL LUNG DISEASE; LIVER DISEASE; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; MUTATION; NAUSEA; NONHUMAN; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPEATED DRUG DOSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ROS1 GENE; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; VISUAL DISORDER; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DRUG INTERACTIONS; FEMALE; GENE REARRANGEMENT; GENETIC VARIATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MET; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 84869462031     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0311     Document Type: Article

References (181)

1. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139
2. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500
3. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101:13306-13311
4. Cohen MH, Williams GA, Sridhara R et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004;10:1212-1218
5. Johnson JR, Cohen M, Sridhara R et al. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 2005;11:6414-6421
6. Maemondo M, Inoue A, Kobayashi K. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-2388
7. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with nonsmall- cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010;11: 121-128
8. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-246
9. Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study Lancet Oncol 2011;12:735-742
10. Yang JC-H, Schuler MH, Yamamoto N et al. LUXLung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol 2012;30 (suppl): LBA7500
11. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers: A different disease. Nat Rev Cancer 2007;7:778-790
12. Toh CK, Gao F, Lim WT et al. Never-smokers with lung cancer: Epidemiologic evidence of a distinct disease entity. J Clin Oncol 2006;24:2245-2251
13. Fukuoka M, Wu YL, Thongprasert S et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011;29:2866-2874
14. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957
15. Han JY, Park K, Kim SW et al. First-SIGNAL: First-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012;30:1122-1128
16. Pao W, Girard N. New driver mutations in nonsmall- cell lung cancer. Lancet Oncol 2011;12:175-180
17. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-566
18. Soda M, Takada S, Takeuchi K et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S A 2008;105:19893-19897
19. Rikova K, Guo A, Zeng Q et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-1203
20. Morris SW, Naeve C, Mathew P et al. ALK, the chromosome 2 gene locus altered by the t(2;5) in non- Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 1997;14:2175-2188
21. Iwahara T, Fujimoto J, Wen D et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 1997;14:439-449
22. Morris SW, Kirstein MN, Valentine MB et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994;263: 1281-1284
23. Barreca A, Lasorsa E, Riera L et al. Anaplastic lymphoma kinase in human cancer. J Mol Endocrinol 2011;47:R11-R23
24. Chiarle R, Voena C, Ambrogio C et al. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008;8:11-23
25. Lee HH, Norris A, Weiss JB et al. Jelly belly protein activates the receptor tyrosine kinase Alk to specify visceral muscle pioneers. Nature 2003;425:507-512
26. Stoica GE, Kuo A, Aigner A et al. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol Chem 2001;276:16772-16779
27. Stoica GE, Kuo A, Powers C et al. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem 2002;277: 35990-35998
28. Bowden ET, Stoica GE, Wellstein A. Anti-apoptotic signaling of pleiotrophin through its receptor, anaplastic lymphoma kinase. J Biol Chem 2002;277:35862-35868
29. Motegi A, Fujimoto J, Kotani M et al. ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth. J Cell Sci 2004;117:3319-3329
30. Perez-Pinera P, Zhang W, Chang Y et al. Anaplastic lymphoma kinase is activated through the pleiotrophin/ receptor protein-tyrosine phosphatase beta/zeta signaling pathway: An alternative mechanism of receptor tyrosine kinase activation. J Biol Chem 2007;282: 28683-28690
31. Reiff T, Huber L, Kramer M et al. Midkine and Alk signaling in sympathetic neuron proliferation and neuroblastoma predisposition. Development 2011;138:4699-4708
32. Mehlen P, Bredesen DE. Dependence receptors: From basic research to drug development. Sci Signal 2011; 4:mr2
33. Mourali J, Benard A, Lourenco FC et al. Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage. Mol Cell Biol 2006;26:6209-6222
34. Bilsland JG, Wheeldon A, Mead A et al. Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications. Neuropsychopharmacology 2008;33:685-700
35. Mosse ́ YP, Laudenslager M, Longo L et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008;455:930-935
36. Chen Y, Takita J, Choi YL et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008;455: 971-974
37. George RE, Sanda T, Hanna M et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008;455:975-978
38. Janoueix-Lerosey I, Lequin D, Brugieres L et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008;455: 967-970
39. Koivunen JP, Mermel C, Zejnullahu K et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008;14:4275-4283
40. McDermott U, Iafrate AJ, Gray NS et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 2008;68:3389-3395
41. Zhang S, Wang F, Keats J et al. Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Des 2011;78: 999-1005
42. Takezawa K, Okamoto I, Nishio K et al. Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer. Clin Cancer Res 2011;17:2140-2148
43. Sequist LV, Heist RS, Shaw AT et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 2011;22: 2616-2624
44. Solomon B, Varella-Garcia M, Camidge DR. ALK gene rearrangements: A new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol 2009;4:1450-1454
45. Tiseo M, Gelsomino F, Bartolotti M et al. Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer. Expert Rev Anticancer Ther 2011;11:1677-1687
46. Doebele RC, Lu X, Sumey C et al. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer 2012;;118:4502-4511
47. Kris MG, Johnson BE, Kwiatkowski DJ et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 2011;29(suppl):7506
48. Kuo YW, Wu SG, Ho CC et al. Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation. J Thorac Oncol 2010;5:2039-2040
49. Martelli MP, Sozzi G, Hernandez L et al. EML4- ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. AmJ Pathol 2009;174:661-670
50. Popat S, Vieira de AA, Min T et al. Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib. J Thorac Oncol 2011;6:1962-1963
51. Sasaki T, Koivunen J, Ogino A et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011;71: 6051-6060
52. Tiseo M, Gelsomino F, Boggiani D et al. EGFR and EML4-ALK gene mutations in NSCLC: A case report of erlotinib-resistant patient with both concomitant mutations. Lung Cancer 2011;71:241-243
53. Yang J, Zhang X, Su J et al. Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. J Clin Oncol 2011;29(suppl):10517
54. Zhang X, Zhang S, Yang X et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer 2010;9: 188
55. Lee JK, Kim TM, Koh Y et al. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation. Lung Cancer 2012;77:460-463
56. Rimkunas VM, Crosby K, Kelly M et al. Analysis of receptor tyrosine kinase ROS1 positive tumors in nonsmall cell lung cancer: Identification of a FIG-ROS1 fusion. Clin Cancer Res 2012;18:4449-4457
57. Peters S, Blackhall F, Boffetta P et al. Building a comprehensive database for the LUNGSCAPE project: A way to bridge genomics and clinicial practice in the European Thoracic Oncology Platform (ETOP). J Thorac Oncol 2011;6:S994
58. Varella-Garcia M, Berry LD, Su P-F et al. ALKand MET genes in advanced lung adenocarcinomas: The Lung Cancer Mutation Consortium experience. J Clin Oncol 2012;30(suppl):7589
59. Li T, Huang E, Desai S et al. Update on the largescale screening of ALK fusion oncogene transcripts in archival NSCLC tumor specimens using multiplexed RT-PCR assays. J Clin Oncol 2012;30(suppl):7594
60. Heuckmann JM, Balke-Want H, Malchers F et al. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin Cancer Res 2012;18:1-9
61. Inamura K, Takeuchi K, Togashi Y et al. EML4- ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008;3:13-17
62. Inamura K, Takeuchi K, Togashi Y et al. EML4- ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 2009;22:508-515
63. Jokoji R, Yamasaki T, Minami S et al. Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALKpositive lung adenocarcinoma. J Clin Pathol 2010;63: 1066-1070
64. Wong DW, Leung EL, So KK et al. The EML4- ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009;115:1723-1733
65. Rodig SJ, Mino-Kenudson M, Dacic S et al. Unique clinicopathologic features characterize ALKrearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009;15:5216-5223
66. Shaw AT, Yeap BY, Mino-Kenudson M et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27:4247-4253
67. Yoshida A, Tsuta K, Watanabe SI et al. Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component. Lung Cancer 2011;72:309-315
68. Yoshida A, Tsuta K, Nakamura H et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol 2011;35:1226-1234
69. Takeuchi K, Soda M, Togashi Y et al. RET, ROS1, and ALK fusions in lung cancer. Nat Med 2012;18:378-381
70. Nishino M, Klepeis VE, Bergethon K et al. Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas. Mod Pathol 2012; 25(suppl): 285A.
71. Choi YL, Takeuchi K, Soda M et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 2008;68: 4971-4976
72. Doebele RC, Pilling AB, Aisner DL et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012;18:1472-1482
73. Sanders HR, Li HR, Bruey JM et al. Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer. Cancer Genet 2011; 204:45-52
74. Takahashi T, Sonobe M, Kobayashi M et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol 2010;17: 889-897
75. Takeuchi K, Choi YL, Soda M et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 2008;14:6618-6624
76. Takeuchi K, Choi YL, Togashi Y et al. KIF5BALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009;15: 3143-3149
77. Wang R, Pan Y, Li C et al. The use of quantitative real-time reverse transcriptase PCR for 5′ and 3′ protions of ALK transcripts to detect ALK rearrangements in lung cancers. Clin Cancer Res 2012;18:4725-4732
78. Penzel R, Schirmacher P, Warth A. A novel EML4-ALK variant. Exon 6 of EML4 fused to exon 19 of ALK. J Thorac Oncol 2012;7:1198-1199
79. Wong DW, Leung EL, Wong SK et al. A novel KIF5B-ALK variant in nonsmall cell lung cancer. Cancer 2011;117:2709-2718
80. Togashi Y, Soda M, Sakata S et al. KLC1-ALK: A novel fusion in lung cancer identified using a formalinfixed paraffin-embedded tissue only. PLoS One 2012;7: e31323
81. Jung Y, Kim P, Jung Y et al. Discovery of ALK- PTPN3 gene fusion from human non-small cell lung carcinoma cell line using next generation RNA sequencing. Genes Chromosomes Cancer 2012;51:590-597
82. Heuckmann JM, Balke-Want H, Malchers F et al. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin Cancer Res 2012;18:4682-4690
83. Takeda M, Okamoto I, SakaiKet al. Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum- based chemotherapy. Ann Oncol 2012 Jul 5. doi: 10.1093/annonc/mds124 [Epub ahead of print].
84. Fukuyoshi Y, Inoue H, Kita Y et al. EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers. Br J Cancer 2008;98:1536-1539
85. Lin E, Li L, Guan Y et al. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and nonsmall cell lung cancers. Mol Cancer Res 2009;7:1466-1476
86. Sugawara E, Togashi Y, Kuroda N et al. Identification of anaplastic lymphoma kinase fusions in renal cancer: Large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method. Cancer 2012;118:4427-4436
87. Hirokawa N, Takemura R. Molecular motors and mechanisms of directional transport in neurons. Nat Rev Neurosci 2005;6:201-214
88. Kohno T, Ichikawa H, Totoki Y et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med 2012;18:375-377
89. Lipson D, Capelletti M, Yelensky R et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012;18:382-384
90. Ju YS, Lee WC, Shin JY et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res 2012;22:436-445
91. Pollmann M, Parwaresch R, dam-Klages S et al. Human EML4, a novel member of the EMAP family, is essential for microtubule formation. Exp Cell Res 2006; 312:3241-3251
92. Sasaki T, Rodig SJ, Chirieac LR et al. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010;46:1773-1780
93. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703
94. Nakajima T, Kimura H, Takeuchi K et al. Treatment of lung cancer with an ALK inhibitor after EML4- ALK fusion gene detection using endobronchial ultrasound-guided transbronchial needle aspiration. J Thorac Oncol 2010;5:2041-2043
95. Perner S, Wagner PL, Demichelis F et al. EML4- ALK fusion lung cancer: A rare acquired event. Neoplasia 2008;10:298-302
96. Shinmura K, Kageyama S, Tao H et al. EML4- ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. Lung Cancer 2008;61:163-169
97. Wu SG, Kuo YW, Chang YL et al. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR. J Thorac Oncol 2012;7:98-104
98. Shaw AT, Yeap BY, Solomon BJ et al. Effect of crizotinib on overall survival in advanced NSCLC harboring anaplastic lymphoma kinase gene rearrangement: A retrospective analysis. Lancet Oncol 2011;11:1004-1012
99. Altavilla G, Santarpia M, Arrigo C et al. EML4- ALK fusion gene in lung adenocarcinoma: A retrospective analysis of the outcome of cisplatin plus pemetrexed treated patients. J Clin Oncol 2010;28(suppl):7610
100. Camidge DR, Kono SA, Lu X et al. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progressionfree survival on pemetrexed. J Thorac Oncol 2011;6: 774-780
101. Lee JO, Kim TM, Lee SH et al. Anaplastic lymphoma kinase translocation: A predictive biomarker of pemetrexed in patients with non-small cell lung cancer. J Thorac Oncol 2011;6:1474-1480
102. Shaw AT, Varghese AM, Solomon BJ et al. Pemetrexed- based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. Ann Oncol 2012 Aug 10. doi: 10.1093/annonc/mds242 [Epub ahead of print].
103. Scagliotti G, Kim DW, Shaw AT et al. A large retrospective analysis of the activity of pemetrexed (PEM) in patients (pts) with ALK-positive (ALK+) non-small cell lung cancer (NSCLC) prior to crizotinib (CRIZ). J Clin Oncol 2012;30(suppl):7599
104. Pfizer Inc. Pfizer announces positive results from phase 3 study PROFILE 1007 evaluating Xalkori (crizotinib) in previously treated patients with ALK-positive advanced non-small cell lung cancer. Available at http:// www.marketwatch.com/story/pfizer-announces-positiveresults- from-phase-3-study-profile-1007-evaluatingxalkorir- crizotinib-in-previously-treated-patients-withalk- positive-advanced-non-small-cell-lung-cancer- 2012-06-19. Accessed June 19, 2012
105. Zhang XC, Blanckmeister C, Yang J et al. Retrospective study of clinicopathologic factors associated with ALK rearrangement and survival outcome in Chinese patients with NSCLC. Abstract presented at: American Association for Cancer Research Annual Meeting; March 31-April 4, 2012; Chicago, IL.
106. Lee JK, Park HS, Kim DW et al. Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer. Cancer 2012;118: 3579-3586
107. Kim HR, Shim HS, Chung JH et al. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer 2012;118: 729-739
108. Yang P, Kulig K, Boland JM et al. Worse diseasefree survival in never-smokers with ALK+ lung adenocarcinoma. J Thorac Oncol 2012;7:90-97
109. Timofeevski SL, McTigue MA, Ryan K et al. Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. Biochemistry 2009;48:5339-5349
110. Zou HY, Li Q, Lee JH et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007; 67:4408-4417
111. Cui JJ, Tran-Dube M, Shen H et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymalepithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 2011;54:6342-6363
112. RCSB Protein Database. X-ray structure of PF- 02341066 bound to the kinase domain of c-MET. Available at http://www.rcsb.org/pdb/explore.do?structureId_ 2wgj. Accessed June 27, 2012
113. RCSB Protein Database. Structure of the human anaplastic lymphoma kinase in complex with crizotinib (PF-02341066). Available at http://www.rcsb.org/pdb/ explore/explore.do?pdbId_2xp2. Accessed June 27, 2012
114. Christensen JG, Zou HY, Arango ME et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007;6:3314-3322
115. Cullinane C, Dorow DS, Jackson S et al. Differential (18)F-FDG and 3′-deoxy-3′-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models. J Nucl Med 2011;52:1261-1267
116. Kwak EL, Camidge DR, Clark J et al. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. J Clin Oncol 2009;27(suppl):3509
117. Pfizer, Inc. Xalkori prescribing information. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202570s000lbl.pdf. Accessed October 7, 2011
118. Tan W, Wilner KD, Bang Y et al. Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients. J Clin Oncol 2010;28(suppl):2596
119. Ou SI, Salgia R, Clark J et al. Comparison of crizotinib (PF-02341066) pharmacokinetics between Asian and non-Asian patients with advanced malignancies. J Thorac Oncol 2010;5:S382
120. French J, Tan W, Kang D et al. Preliminary exposure- response analysis of crizotinib in patients with ALK-positive advanced non-small cell lung cancer. Poster presented at: American Society for Clinical Pharmacology and Therapeutics Annual Meeting; March 12-17, 2012; National Harbor, MD.
121. Camidge DR, Bang Y, Kwak EL et al. Progression- free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive nonsmall cell lung cancer (NSCLC). Presented at: 47th Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2011: Chicago, IL.
122. Camidge DR, Bang Y, Kwak EL et al. Efficacy and safety of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer: Updated results from the molecularly defined cohort of this first-inman phase I study. Lancet Oncol 2012 Sep 3. doi: 10.1016/S1470204512703443 [Epub ahead of print].
123. Kim D-W, Ahn M-J, Shi Y et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). Poster presented at: 48th Annual Meeting of the American Society of Clinical Oncology; June 1-5, 2012; Chicago, IL.
124. Kim DW, Blackhall F, Soria JC et al. A global phase 2 study including efficacy, safety and patientreported outcomes (PROs) with crizotinib in patients (Pts) with ALK-positive non-small cell lung cancer (NSCLC). Eur J Cancer 2011;47:S617
125. Besse B, Salgia R, Solomon B et al. Visual disturbances in patients (pts) with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) treated with crizotinib. Poster presented at: European Society of Medical Oncology Annual Meeting; September 28-October 2, 2012; Vienna, Austria.
126. Schnell P, Safferman AZ, Bartlett CH, Tang Y, Wilner KD. Clinical presentation of hepatotoxicity-associated crizotinib in ALK-positive (ALK+) advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2012; 30(suppl):7598
127. Weickhardt AJ, Rothman MS, Salian-Mehta S et al. Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer 2012 Apr 4. doi: 10.1002/cncr.27450 [Epub ahead of print].
128. Costa DB, Kobayashi S, Pandya SS et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 2011;29:e443-e445
129. Otterson GA, Riely GJ, Shaw AT et al. Clinical characteristics of ALK+ NSCLC patients (pts) treated with crizotinib beyond disease progression (PD): Potential implications for management. J Clin Oncol 2012; 30(suppl):7600
130. Weickhardt JA, Scheier B, Burke JM et al. Continuation of EGFR/ALK inhibition after local therapy of oligoprogressive disease in EGFR mutant (Mt) and ALK+ non-small cell lung cancer (NSCLC). J Clin Oncol 2012;30(suppl):7526
131. Crino L, Kim D-W, Riely G et al. Initial phase 2 results with crizotinib in advanced ALK-positive nonsmall cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol 2011;29(suppl):7514
132. Tomlins SA, Rhodes DR, Perner S et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-648
133. Boland JM, Erdogan S, Vasmatzis G et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional upregulation in non-small cell lung carcinomas. Hum Pathol 2009;40:1152-1158
134. Camidge DR, Kono SA, Flacco A et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 2010;16:5581-5590
135. McLeer-Florin A, Moro-Sibilot D, Melis A et al. Dual IHC and FISH testing for alk gene rearrangement in lung adenocarcinomas in a routine practice: A French study. J Thorac Oncol 2012;7:348-354
136. Yoshida A, Tsuta K, Nitta H et al. Bright-field dual- color chromogenic in situ hybridization for diagnosing echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinomas. J Thorac Oncol 2011;6:1677-1686
137. Camidge DR, Theodoro M, Maxson DA et al. Correlations between the percentage of tumor cells showing an ALK (anaplastic lymphoma kinase) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization- positive nonsmall cell lung cancer. Cancer 2012; 118:4486-4494
138. Paik JH, Choe G, Kim H et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: Correlation with fluorescence in situ hybridization. J Thorac Oncol 2011;6:466-472
139. Debelenko LV, Raimondi SC, Daw N et al. Renal cell carcinoma with novel VCL-ALK fusion: New representative of ALK-associated tumor spectrum. Mod Pathol 2011;24:430-442
140. Marino-Enriquez A, Ou WB, Weldon CB et al. ALK rearrangement in sickle cell trait-associated renal medullary carcinoma. Genes Chromosomes Cancer 2011;50:146-153
141. College of American Pathologists, International Association for the Study of Lung Cancer, Association for Molecular Pathology. Lung cancer biomarkers guideline draft recommendations. Available at http://www.cap.org/apps/docs/membership/transformation/new/ lung_public_comment_supporting_materials.pdf. Accessed March 6, 2012
142. Garcia-Caballero T, Grabau D, Green AR et al. Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: A European multicentre study involving 168 specimens. Histopathology 2010;56:472-480
143. Kim H, Yoo SB, Choe JY et al. Detection of ALK gene rearrangement in non-small cell lung cancer: A comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J Thorac Oncol 2011;6:1359-1366
144. Mino-Kenudson M, Chirieac LR, Law K et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 2010; 16:1561-1571
145. National Comprehensive Cancer Network (NCCN). Guidelines for Management of Stage IV NSCLC. NCCN guidelines version 2, 2012. National Comprehensive Cancer Network®, Fort Washington, PA, USA.
146. Riely GJ, Chaft JE, LadanyiMet al. Incorporation of crizotinib into the NCCN guidelines. J Natl Compr Canc Netw 2011;9:1328-1330
147. Ellis PM, Blais N, Soulieres D et al. A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. J Thorac Oncol 2011;6:1379-1391
148. Choi YL, Soda M, Yamashita Y et al. EML4- ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010;363:1734-1739
149. Katayama R, Shaw AT, Khan TM et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 2012;4:120-17
150. Lovly CM, Pao W. Escaping ALK inhibition: Mechanisms of and strategies to overcome resistance. Sci Transl Med 2012;4:120ps2
151. Sasaki T, Okuda K, Zheng W et al. The neuroblastoma- associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res 2010;70:10038-10043
152. Heuckmann JM, Holzel M, Sos ML et al. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin Cancer Res 2011;17: 7394-7401
153. Sasaki T, Janne PA. New strategies for treatment of ALK rearranged non-small cell lung cancers. Clin Cancer Res 2011;17:7213-7218
154. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010;10:760-774
155. Katayama R, Khan TM, Benes C et al. Therapeutic strategies to overcome crizotinib resistance in nonsmall cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A 2011;108:7535-7540
156. Sakamoto H, Tsukaguchi T, Hiroshima S et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011; 19:679-690
157. Lovly CM, Heuckmann JM, de SE et al. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res 2011;71:4920-4931
158. Sequist LV, Gettinger S, Senzer NN et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 2010;28:4953-4960
159. Wong K, Koczywas M, Goldman JW et al. An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2011;29 (suppl): abstr 7500
160. Normant E, Paez G, West KA et al. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene 2011;30:2581-2586
161. Faber A, Corcoran RB, Ebi H et al. BIM expression in treatment naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov 2011;1:352-365
162. Lennerz JK, Kwak EL, Ackerman A et al. MET Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib. J Clin Oncol 2011;29:4803-4810
163. Ou SH, Kwak EL, Siwak-Tapp C et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 2011; 6:942-946
164. Chi AS, Kwak EL, Clark JW et al. Clinical improvement and rapid radiographic regression induced by a MET inhibitor in a patient with MET-amplified glioblastoma. J Clin Oncol 2011;29(suppl):2072
165. Pogliani EM, Dilda I, Villa F et al. High response rate to crizotinib in advanced, chemoresistant ALK+ lymphoma patients. J Clin Oncol 2011;29(suppl): e18507
166. Mossé YP, Balis FM, Lim MS et al. Efficacy of crizotinib in children with relapsed/refractory ALKdriven tumors including anaplastic large cell lymphoma and neuroblastoma: A Children's Oncology Group phase I consortium study. J Clin Oncol 2012;30(suppl): 9500
167. Rimkunas V, Crosby K, Kelly M et al. Frequencies of ALK and ROS in NSCLC FFPE tumor samples utilizing a highly specific immunohistochemistry-based assay and FISH analysis. J Clin Oncol 2010;28(suppl): 10536
168. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001;411:355-365
169. Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene 2000;19:5548-5557
170. Sonnenberg-Riethmacher E, Walter B, Riethmacher D et al. The c-ros tyrosine kinase receptor controls regionalization and differentiation of epithelial cells in the epididymis. Genes Dev 1996;10:1184-1193
171. Davies KD, Le AT, Theodoro MF et al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clinc Cancer Res 2012;18:4570-4579
172. Bergethon K, Shaw AT, Ignatius Ou SH et al. ROS1 Rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012;30:863-870
173. Li C, Fang R, Sun Y et al. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS One 2011;6:e28204
174. Shaw AT, Camidge DR, Engelman JA et al. Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. Presented at: 48th Annual Meeting of the American Society of Clinical Oncology; June 1-5, 2012; Chicago, IL.
175. Charest A, Lane K, McMahon K et al. Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21). Genes Chromosomes Cancer 2003;37:58-71
176. Gu TL, Deng X, Huang F et al. Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One 2011;6:e15640
177. de KA, van Kessel AG, Grosveld G et al. A cellular oncogene is translocated to the Philadelphia chro- mosome in chronic myelocytic leukaemia. Nature 1982; 300:765-767
178. Cohen MH, Williams G, Johnson JR et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002;8:935-942
179. Mitelman F, Johansson B, Mertens F. Fusion genes and rearranged genes as a linear function of chromosome aberrations in cancer. Nat Genet 2004;36:331-334
180. Sequist LV, Waltman BA, as-Santagata D et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26
181. Dagher R, Cohen M, Williams G et al. Approval summary: Imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 2002;8:3034-3038.